
CRC One of the Most Common Types of Cancer Worldwide
Mainz Biomed enrolls 1st patient in its eAArly DETECT 2 Clinical Study. 2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples. Study is on track to report Top-Line Results in fourth quarter 2025.